Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mefenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 3/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mefenamic Acid SCHEMBL29355128 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL3544 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL29350572 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL6421234 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL27396077 | 0.98 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL27621964 | 0.98 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL28663310 | 0.98 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL29282578 | 0.98 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL28036729 | 0.98 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL678182 | 0.98 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853628-B | Docosahexaenoic acid acyl ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2023-10-13 | — | — | CN | claimed |
| CN-114853628-A | Docosahexaenoic acid ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2022-08-05 | — | — | CN | claimed |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-05-06 | — | — | US | disclosed |
| EP-4466251-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS INC. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118986994-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118556043-A | Treatment of signs, symptoms and/or complications of viral, bacterial, protozoal and/or fungal infections by highly penetrating prodrugs | 苏州泰飞尔医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-113164494-B | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-08-27 | — | — | CN | disclosed |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117355527-A | External anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-114853628-B | Docosahexaenoic acid acyl ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023134733-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| CN-116410117-A | Preparation method and application of isocyanate compound | 深圳福山生物科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-115996715-A | Treatment of viral conjunctivitis | 奥可金公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-114853628-A | Docosahexaenoic acid ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2022-08-05 | — | — | CN | disclosed |
| CN-107540697-B | Compound, photosensitive resin composition containing same, and color filter | 三星SDI株式会社 | 2022-05-31 | — | — | CN | disclosed |
| CN-110256375-B | Mefenamic acid-piperazine salt type and preparation method thereof | 天津大学 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | PTGS2 37/4885PTGS1 16/4885AKR1C3 489/4885 |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | JAK1, TNF, CYP4A11 | PTGS2 37/4885PTGS1 16/4885AKR1C3 489/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | PTGS2 37/4885PTGS1 16/4885AKR1C3 489/4885 |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TNF, CYP4A11, JAK1 | PTGS2 36/4885PTGS1 16/4885AKR1C3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.